Download MendeleyDiscovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.
Parcella, K., Wang, T., Eastman, K., Zhang, Z., Yin, Z., Patel, M., Tu, Y., Zheng, B.Z., Walker, M.A., Saulnier, M.G., Frennesson, D., Bowsher, M., Gillis, E., Peese, K., Belema, M., Cianci, C., Dicker, I.B., McAuliffe, B., Ding, B., Falk, P., Simmermacher, J., Parker, D.D., Sivaprakasam, P., Kish, K., Lewis, H., Hanumegowda, U., Jenkins, S., Kadow, J.F., Krystal, M., Meanwell, N.A., Naidu, B.N.(2022) ACS Med Chem Lett 13: 972-980
- PubMed: 35707159
- DOI: https://doi.org/10.1021/acsmedchemlett.2c00115
- Primary Citation of Related Structures:
7UOQ - PubMed Abstract:
Allosteric HIV-1 integrase inhibitors (ALLINIs) have been of interest recently because of their novel mechanism of action. Strategic modifications to the C5 moiety of a class of 4-(4,4-dimethylpiperidinyl)-2,6-dimethylpyridinyl ALLINIs led to the identification of a tetrahydroisoquinoline heterocycle as a suitable spacer element to project the distal hydrophobic aryl ring. Subsequent optimization of the aryl substitutions identified 12 as an ALLINI with single-digit nanomolar inhibitory potency and low clearance across preclinical species. In preclinical toxicology studies with 12 in rats, lipid hepatocellular vacuolation was observed. Removal of the C6 methyl group resulted in GSK3839919 ( 22 ), which exhibited a reduced incidence and severity of lipid vacuolation in both in vitro assays and in vivo studies while maintaining the potency and pharmacokinetic (PK) properties of the prototype. The virology, PK, and toxicology profiles of 22 are discussed.
Organizational Affiliation:
ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States.
